CP1.AX - Cannpal Animal Therapeutics Limited

ASX - ASX Delayed price. Currency in AUD

Cannpal Animal Therapeutics Limited

45a Bay Street
Level 3
Double Bay, NSW 2028
61 2 6108 3622

IndustryDrug Manufacturers—Specialty & Generic
Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Layton Patrick MillsFounder, MD & Director216.85kN/AN/A
Dr. Margaret CurtisHead of Clinical Devel. and R&D179.32kN/AN/A
Mr. Baden Maxwell BowenCFO & Company Sec.N/AN/AN/A
Dr. Rayson TanChief Scientific Officer & Member of Advisory BoardN/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


CannPal Animal Therapeutics Limited engages in the research and development of animal health products in Australia. It develops CPAT-01, a cannabis-derived pharmaceutical product to provide veterinarians and pet owners to treat animals. The company was incorporated in 2016 and is based in Double Bay, Australia.

Corporate governance

Cannpal Animal Therapeutics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.